Identification
NameEslicarbazepine acetate
Accession NumberDB09119
TypeSmall Molecule
GroupsApproved
Description

Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. Eslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of voltage-gated sodium channels, thus preventing their return to the activated state during which seizure activity can occur.

Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food. Eslicarbazepine acetate is associated with numerous side effects including dizziness, drowsiness, nausea, vomiting, diarrhea, headache, aphasia, lack of concentration, psychomotor retardation, speech disturbances, ataxia, depression and hyponatremia. It is recommended that patients taking eslicarbazepine acetate be monitored for suicidality.

Structure
Thumb
Synonyms
(10S)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide
(10S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate
ESL
Stedesa
External IDs BIA 2-093 / BIA-2-093 / BIA2-093 / SEP 0002093 / SEP-0002093 / SEP0002093
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AptiomTablet200 mgOralSunovion2014-08-07Not applicableCanada
AptiomTablet200 mg/1OralSunovion2014-04-07Not applicableUs
AptiomTablet800 mgOralSunovion2014-08-07Not applicableCanada
AptiomTablet800 mg/1OralSunovion2014-04-07Not applicableUs
AptiomTablet400 mgOralSunovion2014-08-07Not applicableCanada
AptiomTablet400 mg/1OralSunovion2014-04-07Not applicableUs
AptiomKitOralSunovion2014-04-07Not applicableUs
AptiomTablet600 mgOralSunovion2014-08-07Not applicableCanada
AptiomTablet600 mg/1OralSunovion2014-04-07Not applicableUs
ZebinixTablet400 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet600 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet200 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet600 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet400 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet400 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet600 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet200 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet400 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet400 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet600 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet600 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet200 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet800 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
ZebinixTablet400 mgOralBial Portela & Ca, S.A.2009-04-21Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Eksaliyef Bial-Portela & Ca. S.A.
ErelibBial-Portela & Ca. S.A.
EslicarEmcure Pharmaceuticals Ltd
EslifyTorrent Pharmaceuticals Ltd
EslistarLupin Ltd
Eslizen Intas Pharmaceuticals Ltd
Exalief Bial-Portela & Ca. S.A.
NormictalAbbott India Ltd
ZebinixBial-Portela & Ca. S.A., Esai Co. Ltd.
ZefretolSun Pharma Laboratories Ltd
Brand mixturesNot Available
Categories
UNIIBEA68ZVB2K
CAS number236395-14-5
WeightAverage: 296.326
Monoisotopic: 296.116092383
Chemical FormulaC17H16N2O3
InChI KeyQIALRBLEEWJACW-INIZCTEOSA-N
InChI
InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
IUPAC Name
(9S)-2-carbamoyl-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-9-yl acetate
SMILES
CC(=O)O[[email protected]]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12
Pharmacology
Indication

Eslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partial-onset seizures that are not adequately controlled with conventional therapy in epileptic patients.

Structured Indications
Pharmacodynamics

Eslicarbazepine acetate is associated with a dose- and concentration-dependant increase in heart rate and prolongation of PR interval.

Mechanism of action

Eslicarbazepine acetate is converted to the active metabolite eslicarbazepine which carries out its anticonvulsant activity. The exact mechanism of action is unknown, but it is thought to involve the inhibition of voltage-gated sodium channels. In in vitro electrophysiological studies, eslicarbazepine was shown to inhibit repeated neuronal firing by stabilizing the inactivated state of voltage-gated sodium channels and preventing their return to the activated state. In vitro studies also showed eslicarbazepine inhibiting T-type calcium channels, which likely also has a role in anticonvulsant activity.

TargetKindPharmacological actionActionsOrganismUniProt ID
P2X purinoceptor 4Proteinyes
antagonist
HumanQ99571 details
Related Articles
Absorption

Eslicarbazepine active metabolite has a high bioavailability and reaches peak serum concentration 1-4 hours after a given dose. Eslicarbazepine acetate absorption is not affected by food.

Volume of distribution

The apparent volume of distribution of eslicarbazepine is 61.3 L for a body weight of 70 kg based on population PK analysis.

Protein binding

Eslicarbazepine is bound to plasma proteins at a relatively low rate of <40%, independent of concentration. In vitro studies have shown that plasma protein binding is not relevantly affected by the presence of other medications such as warfarin, diazepam, digoxin, phenytoin or tolbutamide. Similarly, the binding of these medications was not significantly affected by the presence of eslicarbazepine.

Metabolism

Eslicarbazepine acetate is rapidly and extensively metabolized to its major active metabolite, eslicarbazepine, via hydrolytic first-pass metabolism. Eslicarbazepine corresponds to about 92% of systemic exposure. Minor active metabolites (R)-licarbazepine and oxcarbazepine consist of <5% of systemic exposure. Active metabolites are then metabolized to inactive glucuronides that correspond to about 3% of systemic exposure.

Eslicarbazepine had a moderate inhibitory effect on CYP2C19 and a mild activation of UGT1A1-mediated glucuronidation when studied in human hepatic microsomes. It has been shown to induce CYP3A4 enzymes in vivo.

SubstrateEnzymesProduct
Eslicarbazepine acetate
Not Available
Eslicarbazepine [(S)-licarbazepine]Details
Eslicarbazepine [(S)-licarbazepine]
Not Available
OxcarbazepineDetails
Oxcarbazepine
Not Available
R-licarbazepineDetails
Oxcarbazepine
Not Available
10-hydroxycarbazepine sulfateDetails
Oxcarbazepine
Not Available
10-hydroxycarbazepine glucuronideDetails
Eslicarbazepine [(S)-licarbazepine]
Not Available
Eslicarbazepine-O-glucuronideDetails
Route of elimination

Eslicarbazepine acetate and its metabolites are eliminated primarily via renal excretion. Eslicarbazepine active metabolite is excreted two-thirds in the unchanged form and one-third as a glucuronide conjugate. This accounts for around 90% of total metabolites excreted, with the remaining 10% being minor metabolites. Renal tubular reabsorption is expected to occur with eslicarbazepine.

Half life

The apparent plasma half-life of eslicarbazepine is 10-20 hours in healthy subjects and 13-20 hours in epilepsy patients. Steady-state plasma concentrations are attained after 4 to 5 days of once daily dosing.

Clearance

Renal clearance of eslicarbazepine was found to be approximately 20 mL/min in healthy subjects with normal renal function.

Toxicity

There are no adequate and well-controlled studies of the use of eslicarbazepine acetate in pregnant women. In studies conducted in pregnant mice, rats, and rabbits, eslicarbazepine acetate did show developmental toxicities, including teratogenicity, embryolethality, and fetal growth retardation, at clinically relevant doses. Drug-induced liver injury ranging from mild to moderate elevations in transaminases (>3 times the upper limit of normal) to rare cases with concomitant elevations of total bilirubin (>2 times the upper limit of normal) have been reported with the use of eslicarbazepine. Overdose with eslicarbazepine acetate appears similar to its known adverse reactions and includes symptoms of hyponatremia, dizziness, nausea, vomiting, somnolence, euphoria, oral paraesthesias, ataxia, and diplopia. There is no specific antidote for eslicarbazepine acetate overdose and it should be treated primarily with supportive measures. If required, the drug may be removed by gastric lavage, partially by hemodialysis or inactivated with activated charcoal.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Eslicarbazepine acetate.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Eslicarbazepine acetate.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Eslicarbazepine acetate.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Eslicarbazepine acetate.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Eslicarbazepine acetate.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Eslicarbazepine acetate.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Eslicarbazepine acetate.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Eslicarbazepine acetate.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Eslicarbazepine acetate.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Eslicarbazepine acetate.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Eslicarbazepine acetate.Approved, Vet Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Eslicarbazepine acetate.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Eslicarbazepine acetate.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Eslicarbazepine acetate.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Eslicarbazepine acetate.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Eslicarbazepine acetate.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Eslicarbazepine acetate.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Eslicarbazepine acetate.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Eslicarbazepine acetate.Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Eslicarbazepine acetate.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Eslicarbazepine acetate.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Eslicarbazepine acetate.Approved
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Eslicarbazepine acetate.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Eslicarbazepine acetate.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Eslicarbazepine acetate.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Eslicarbazepine acetate.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Eslicarbazepine acetate.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Eslicarbazepine acetate.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Eslicarbazepine acetate.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Eslicarbazepine acetate.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Eslicarbazepine acetate.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Eslicarbazepine acetate.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Eslicarbazepine acetate.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Eslicarbazepine acetate.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Eslicarbazepine acetate.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Eslicarbazepine acetate.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Eslicarbazepine acetate.Approved, Vet Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Eslicarbazepine acetate.Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Eslicarbazepine acetate.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Eslicarbazepine acetate.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Eslicarbazepine acetate.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Eslicarbazepine acetate.Approved
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Eslicarbazepine acetate.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Eslicarbazepine acetate.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Eslicarbazepine acetate.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Eslicarbazepine acetate.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Eslicarbazepine acetate.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Eslicarbazepine acetate.Approved
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Eslicarbazepine acetate.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Eslicarbazepine acetate.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Eslicarbazepine acetate.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Eslicarbazepine acetate.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Eslicarbazepine acetate.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Eslicarbazepine acetate.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Eslicarbazepine acetate.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Eslicarbazepine acetate.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Eslicarbazepine acetate.Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Eslicarbazepine acetate.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Eslicarbazepine acetate.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Eslicarbazepine acetate.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Eslicarbazepine acetate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Eslicarbazepine acetate.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Eslicarbazepine acetate.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Eslicarbazepine acetate.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Eslicarbazepine acetate.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Eslicarbazepine acetate.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Eslicarbazepine acetate.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Eslicarbazepine acetate.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Eslicarbazepine acetate.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Eslicarbazepine acetate.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Eslicarbazepine acetate.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Eslicarbazepine acetate.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Eslicarbazepine acetate.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Eslicarbazepine acetate.Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Eslicarbazepine acetate.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Eslicarbazepine acetate.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Eslicarbazepine acetate.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Eslicarbazepine acetate.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Eslicarbazepine acetate.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Eslicarbazepine acetate.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Eslicarbazepine acetate.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Eslicarbazepine acetate.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Eslicarbazepine acetate.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Eslicarbazepine acetate.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Eslicarbazepine acetate.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Eslicarbazepine acetate.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Eslicarbazepine acetate.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Eslicarbazepine acetate.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Eslicarbazepine acetate.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Eslicarbazepine acetate.Approved
Fluticasone propionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Eslicarbazepine acetate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
FormoterolThe metabolism of Formoterol can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
FosphenytoinThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Eslicarbazepine acetate.Approved
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Eslicarbazepine acetate.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Eslicarbazepine acetate.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Eslicarbazepine acetate.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Eslicarbazepine acetate.Approved
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Eslicarbazepine acetate.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Eslicarbazepine acetate.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Eslicarbazepine acetate.Approved
HistamineThe serum concentration of Histamine Phosphate can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Eslicarbazepine acetate.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Eslicarbazepine acetate.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Eslicarbazepine acetate.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Eslicarbazepine acetate.Approved
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Eslicarbazepine acetate.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Eslicarbazepine acetate.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Eslicarbazepine acetate.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Eslicarbazepine acetate.Approved
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Eslicarbazepine acetate.Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Eslicarbazepine acetate.Approved
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Eslicarbazepine acetate.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Eslicarbazepine acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Eslicarbazepine acetate.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Eslicarbazepine acetate.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Eslicarbazepine acetate.Approved
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Eslicarbazepine acetate.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Eslicarbazepine acetate.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Eslicarbazepine acetate.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Eslicarbazepine acetate.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Eslicarbazepine acetate.Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Eslicarbazepine acetate.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
MefloquineThe therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Mefloquine.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Eslicarbazepine acetate.Approved, Nutraceutical, Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Eslicarbazepine acetate.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Eslicarbazepine acetate.Approved, Illicit
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Eslicarbazepine acetate.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Eslicarbazepine acetate.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Eslicarbazepine acetate.Experimental
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Eslicarbazepine acetate.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Eslicarbazepine acetate.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Eslicarbazepine acetate.Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Eslicarbazepine acetate.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Eslicarbazepine acetate.Approved
MetoprololThe metabolism of Metoprolol can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Eslicarbazepine acetate.Approved
MianserinThe therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Mianserin.Approved
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Eslicarbazepine acetate.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Eslicarbazepine acetate.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Eslicarbazepine acetate.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Eslicarbazepine acetate.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Eslicarbazepine acetate.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Eslicarbazepine acetate.Approved
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Eslicarbazepine acetate.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Eslicarbazepine acetate.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Eslicarbazepine acetate.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Eslicarbazepine acetate.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Eslicarbazepine acetate.Approved
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Eslicarbazepine acetate.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Eslicarbazepine acetate.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Eslicarbazepine acetate.Approved
OrlistatThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Eslicarbazepine acetate.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Oxcarbazepine.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Eslicarbazepine acetate.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Eslicarbazepine acetate.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Eslicarbazepine acetate.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Eslicarbazepine acetate.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Eslicarbazepine acetate.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Eslicarbazepine acetate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Eslicarbazepine acetate.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Eslicarbazepine acetate.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Eslicarbazepine acetate.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Eslicarbazepine acetate.Approved
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Eslicarbazepine acetate.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
PhenobarbitalThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Eslicarbazepine acetate.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Eslicarbazepine acetate.Approved
PhenytoinThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Eslicarbazepine acetate.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Eslicarbazepine acetate.Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Eslicarbazepine acetate.Approved
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Eslicarbazepine acetate.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Eslicarbazepine acetate.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Eslicarbazepine acetate.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Eslicarbazepine acetate.Approved
PrimidoneThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Eslicarbazepine acetate.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Eslicarbazepine acetate.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Eslicarbazepine acetate.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Eslicarbazepine acetate.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Eslicarbazepine acetate.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Eslicarbazepine acetate.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Eslicarbazepine acetate.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Eslicarbazepine acetate.Approved
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Eslicarbazepine acetate.Approved
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Eslicarbazepine acetate.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Eslicarbazepine acetate.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Eslicarbazepine acetate.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Eslicarbazepine acetate.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Eslicarbazepine acetate.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Eslicarbazepine acetate.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Eslicarbazepine acetate.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Eslicarbazepine acetate.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Eslicarbazepine acetate.Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Eslicarbazepine acetate.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Eslicarbazepine acetate.Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Eslicarbazepine acetate.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Eslicarbazepine acetate.Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Eslicarbazepine acetate.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Eslicarbazepine acetate.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Eslicarbazepine acetate.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Eslicarbazepine acetate.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Eslicarbazepine acetate.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Eslicarbazepine acetate.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Eslicarbazepine acetate.Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Eslicarbazepine acetate.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Eslicarbazepine acetate.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Eslicarbazepine acetate.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Eslicarbazepine acetate.Approved
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Eslicarbazepine acetate.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Eslicarbazepine acetate.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Eslicarbazepine acetate.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Eslicarbazepine acetate.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Eslicarbazepine acetate.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Eslicarbazepine acetate.Approved
ThioridazineThe metabolism of Thioridazine can be decreased when combined with Eslicarbazepine acetate.Withdrawn
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Eslicarbazepine acetate.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Eslicarbazepine acetate.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Eslicarbazepine acetate.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Eslicarbazepine acetate.Approved
TimololThe metabolism of Timolol can be decreased when combined with Eslicarbazepine acetate.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Eslicarbazepine acetate.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Eslicarbazepine acetate.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Eslicarbazepine acetate.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Eslicarbazepine acetate.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Eslicarbazepine acetate.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Eslicarbazepine acetate.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Eslicarbazepine acetate.Approved
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Eslicarbazepine acetate.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Eslicarbazepine acetate.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Eslicarbazepine acetate.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Eslicarbazepine acetate.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Eslicarbazepine acetate.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Eslicarbazepine acetate.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Eslicarbazepine acetate.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Eslicarbazepine acetate.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Eslicarbazepine acetate.Approved
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Eslicarbazepine acetate.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Eslicarbazepine acetate.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Eslicarbazepine acetate.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Eslicarbazepine acetate.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Eslicarbazepine acetate.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Eslicarbazepine acetate.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Eslicarbazepine acetate.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Eslicarbazepine acetate.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Eslicarbazepine acetate.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Eslicarbazepine acetate.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Eslicarbazepine acetate.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Eslicarbazepine acetate.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Eslicarbazepine acetate.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Eslicarbazepine acetate.Approved
Food InteractionsNot Available
References
Synthesis Reference
  • Ravinder B, Reddy SR, Sridhar M, Mohan MM, Srinivas K, Reddy AP, Bandichhor R. An efficient synthesis for eslicarbazepine acetate, oxcarbazepine, and carbamazepine. Tetrahedron Letters. 2013 May 29;54(22):2841-4.
  • Desai S, Poddar A, Sawant K: Formulation of cyclodextrin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability. Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:826-34. doi: 10.1016/j.msec.2015.09.019. Epub 2015 Sep 8. Pubmed.
General References
  1. Banach M, Borowicz KK, Czuczwar SJ: Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):639-48. doi: 10.1517/17425255.2015.1021686. Epub 2015 Mar 5. [PubMed:25740561 ]
  2. Bialer M, White HS: Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010 Jan;9(1):68-82. doi: 10.1038/nrd2997. [PubMed:20043029 ]
  3. Bialer M, Soares-da-Silva P: Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. [PubMed:22612290 ]
  4. Villanueva V, Serratosa JM, Guillamon E, Garces M, Giraldez BG, Toledo M, Salas-Puig J, Lopez Gonzalez FJ, Flores J, Rodriguez-Uranga J, Castillo A, Mauri JA, Camacho JL, Lopez-Gomariz E, Giner P, Torres N, Palau J, Molins A: Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014 Sep;108(7):1243-52. doi: 10.1016/j.eplepsyres.2014.04.014. Epub 2014 May 14. [PubMed:24908564 ]
  5. Soares-da-Silva P, Pires N, Bonifacio MJ, Loureiro AI, Palma N, Wright LC: Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacol Res Perspect. 2015 Mar;3(2):e00124. doi: 10.1002/prp2.124. Epub 2015 Mar 30. [PubMed:26038700 ]
  6. Rocamora R: A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. Ther Adv Neurol Disord. 2015 Jul;8(4):178-86. doi: 10.1177/1756285615589711. [PubMed:26136845 ]
  7. Tomic MA, Pecikoza UB, Micov AM, Stepanovic-Petrovic RM: The Efficacy of Eslicarbazepine Acetate in Models of Trigeminal, Neuropathic, and Visceral Pain: The Involvement of 5-HT1B/1D Serotonergic and CB1/CB2 Cannabinoid Receptors. Anesth Analg. 2015 Dec;121(6):1632-9. doi: 10.1213/ANE.0000000000000953. [PubMed:26465930 ]
  8. Jacobson MP, Pazdera L, Bhatia P, Grinnell T, Cheng H, Blum D: Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurol. 2015 Mar 28;15:46. doi: 10.1186/s12883-015-0305-5. [PubMed:25880756 ]
  9. Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A: Clinical utility of eslicarbazepine: current evidence. Drug Des Devel Ther. 2015 Feb 10;9:781-9. doi: 10.2147/DDDT.S57409. eCollection 2015. [PubMed:25709402 ]
  10. Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, Kowacs PA, Hong SB, Cheng H, Blum D, Nunes T, Soares-da-Silva P: Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015 Feb;56(2):244-53. doi: 10.1111/epi.12894. Epub 2014 Dec 22. [PubMed:25528898 ]
  11. Shaikh S, Rizvi SM, Hameed N, Biswas D, Khan M, Shakil S, Kamal MA: Aptiom (eslicarbazepine acetate) as a dual inhibitor of beta-secretase and voltage-gated sodium channel: advancement in Alzheimer's disease-epilepsy linkage via an enzoinformatics study. CNS Neurol Disord Drug Targets. 2014;13(7):1258-62. [PubMed:25230222 ]
  12. Doeser A, Soares-da-Silva P, Beck H, Uebachs M: The effects of eslicarbazepine on persistent Na(+) current and the role of the Na(+) channel beta subunits. Epilepsy Res. 2014 Feb;108(2):202-11. doi: 10.1016/j.eplepsyres.2013.11.022. Epub 2013 Dec 8. [PubMed:24368131 ]
External Links
ATC CodesN03AF04 — Eslicarbazepine
AHFS Codes
  • 28.12
PDB EntriesNot Available
FDA labelDownload (820 KB)
MSDSDownload (44.8 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentEpilepsies25
1CompletedTreatmentEpilepsy, Localization Related2
1CompletedTreatmentPain, Neuropathic1
1TerminatedTreatmentEpilepsies2
2CompletedNot AvailableEpilepsies1
2CompletedTreatmentBipolar I Disorder2
2CompletedTreatmentEpilepsies2
2CompletedTreatmentEpilepsy, Localization Related1
2CompletedTreatmentFibromyalgia1
2CompletedTreatmentMigraines1
2CompletedTreatmentPainful Diabetic Neuropathy1
2CompletedTreatmentPostherpetic Neuralgia1
2TerminatedTreatmentBipolar I Disorder1
3Active Not RecruitingTreatmentEpilepsy, Localization Related1
3Active Not RecruitingTreatmentPartial Epilepsy in Children and Adolescents1
3CompletedTreatmentEpilepsies3
3CompletedTreatmentEpilepsy With Simple or Complex Partial Onset Seizures1
3CompletedTreatmentEpilepsy, Localization Related2
3CompletedTreatmentRefractory Partial Epilepsy1
3Enrolling by InvitationTreatmentEpilepsies1
3RecruitingTreatmentEpilepsies1
3TerminatedTreatmentPainful Diabetic Neuropathy1
3TerminatedTreatmentPost Herpetic Neuralgia1
4CompletedTreatmentEpilepsies1
4RecruitingTreatmentEpilepsies1
4RecruitingTreatmentEpilepsy With Partial On-set Seizures1
Not AvailableCompletedNot AvailableEpilepsies2
Not AvailableCompletedNot AvailablePartial onset seizure Epilepsy1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
KitOral
TabletOral200 mg
TabletOral200 mg/1
TabletOral400 mg/1
TabletOral400 mg
TabletOral600 mg/1
TabletOral600 mg
TabletOral800 mg/1
TabletOral800 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5753646 No1996-06-272016-06-27Us
US8372431 No2010-04-172030-04-17Us
US9206135 No2006-04-212026-04-21Us
US9643929 No2006-04-212026-04-21Us
US9566244 No2008-10-232028-10-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityWater solubility of eslicarbazepine acetate is low at less than 1 mg/mL including at different pH values. Its main metabolite eslicarbazepine has a greater water solubility of 4.2 mg/mL.# Banach M, Borowicz KK, Czuczwar SJ: Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):639-48. doi: 10.1517/17425255.2015.1021686. Epub 2015 Mar 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25740561
logP8.8# Bialer M, Soares-da-Silva P: Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22612290
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP1.99ALOGPS
logP2.17ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)15.96ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.63 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity81.44 m3·mol-1ChemAxon
Polarizability30.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydrocarbon derivatives. These are derivatives of hydrocarbons obtained by substituting one or more carbon atoms by an heteroatom. They contain at least one carbon atom and heteroatom.
KingdomOrganic compounds
Super ClassHydrocarbon derivatives
ClassNot Available
Sub ClassNot Available
Direct ParentHydrocarbon derivatives
Alternative ParentsNot Available
SubstituentsHydrocarbon derivative / Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsacetate ester, carboxamide, dibenzoazepine (CHEBI:87016 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin.
Gene Name:
P2RX4
Uniprot ID:
Q99571
Uniprot Name:
P2X purinoceptor 4
Molecular Weight:
43368.725 Da
References
  1. Tian M, Abdelrahman A, Weinhausen S, Hinz S, Weyer S, Dosa S, El-Tayeb A, Muller CE: Carbamazepine derivatives with P2X4 receptor-blocking activity. Bioorg Med Chem. 2014 Feb 1;22(3):1077-88. doi: 10.1016/j.bmc.2013.12.035. Epub 2013 Dec 25. [PubMed:24411477 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Bialer M, Soares-da-Silva P: Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. [PubMed:22612290 ]
  2. Bialer M, White HS: Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010 Jan;9(1):68-82. doi: 10.1038/nrd2997. [PubMed:20043029 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Bialer M, Soares-da-Silva P: Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. [PubMed:22612290 ]
  2. Bialer M, White HS: Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010 Jan;9(1):68-82. doi: 10.1038/nrd2997. [PubMed:20043029 ]
Drug created on September 22, 2015 14:02 / Updated on August 08, 2017 11:11